SEC Comment Letter 0000000000-25-007623 to MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252) (MYNZ)
MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252)
Date: July 18, 2025 · CIK: 0001874252 · Accession: 0000000000-25-007623
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Mainz Biomed N.V. Draft Registration Statement on Form F-1 Submitted July 15, 2025 CIK No. 0001874252 Dear Guido Baechler:
July 18, 2025
Guido Baechler Chief Executive Officer Mainz Biomed N.V. Robert Koch Strasse 50 55129 Mainz Germany
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Tim Dockery, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> July 18, 2025 Guido Baechler Chief Executive Officer Mainz Biomed N.V. Robert Koch Strasse 50 55129 Mainz Germany Re: Mainz Biomed N.V. Draft Registration Statement on Form F-1 Submitted July 15, 2025 CIK No. 0001874252 Dear Guido Baechler: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Tim Dockery, Esq. </TEXT> </DOCUMENT>